Companies /Healthcare
Bristol-Myers Squibb Company
NYSE: BMY Drug Manufacturers - General
$61.35
▼ $1.58 (−2.51%) today
Markets closed · 9:16am ET

Bristol-Myers Squibb (BMY) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
BMY vs Market · 30-day return after each reportBMYS&P 500
−6%0%+6%−3.7%+8.1%Q1 25+9.5%+1.3%Q2 25+5.8%+0.3%Q3 25+1.0%−0.1%Q4 25−10.1%+5.7%Q1 26+3.0%+3.4%Q2 26
−6%0%+6%Q1 25Q3 25Q1 26
BMY EPS Trend · estimate vs actualEstimateActual
$0.00$0.60$1.20$1.80$1.50$1.80Q1 25$1.10$1.46Q2 25$1.52$1.63Q3 25$1.20$1.26Q4 25$1.42$1.58Q1 26$1.60$2.04Q2 26$1.23$1.35Q3 26
$0.00$0.60$1.20$1.80Q1 25Q3 25Q1 26Q3 26
BMY Revenue Trend · estimate vs actualEstimateActual
$0$4.0B$8.0B$12.0B$10.7B$11.2BQ1 25$11.4B$12.3BQ2 25$11.8B$12.2BQ3 25$12.3B$12.5BQ4 25$10.9B$11.5BQ1 26$11.7B$13.0BQ2 26$12.7B$13.1BQ3 26
$0$4.0B$8.0B$12.0BQ1 25Q3 25Q1 26Q3 26

How Often Does Bristol-Myers Squibb Beat Earnings Estimates?

Bristol-Myers Squibb beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.

BMY quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Non-GAAP EPS includes a $(0.58) per share net impact from Acquired IPRD charges ($1,558 million) and licensing income; gross margin also reflects a one-time contract termination charge. GAAP EPS of $1.05 additionally reflects $606 million of after-tax specified items, including $458 million amortization of acquired intangibles and $187 million restructuring provision. $1.35 est. $1.23 +9.48% $13.1B est. $12.7B +2.67%
Q2 2026 $2.04 est. $1.60 +27.74% $13.0B est. $11.7B +10.53%
Q1 2026 $1.58 est. $1.42 +11.14% $11.5B est. $10.9B +5.24%
Q4 2025 $1.26 est. $1.20 +4.57% $12.5B est. $12.3B +1.79%
Q3 2025 $1.63 est. $1.52 +7.56% $12.2B est. $11.8B +3.58%
Q2 2025 $1.46 est. $1.10 +32.59% $12.3B est. $11.4B +7.77%
Q1 2025 $1.80 est. $1.50 +19.88% $11.2B est. $10.7B +4.62%

Figures from SEC filings and company reports. Not investment advice.